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Abstract
Background: Fingolimod is the first oral agent used for treatment of relapsing-remitting multiple sclerosis. Macular
edema, but not retinal hemorrhage, is a well-known adverse effect of fingolimod treatment. To the best of our
knowledge, this is the first case report of extensive retinal hemorrhages following fingolimod treatment.
Case presentation: A 31-year-old male with relapsing-remitting multiple sclerosis developed macular edema and
retinal hemorrhages in his left eye, 1 month after starting fingolimod treatment; treatment was then discontinued.
The hemorrhages were flame-shaped, and were extensive along retinal arteries and veins. The hemorrhages started
to decrease at 4 weeks and disappeared completely at 24 weeks after cessation of fingolimod treatment.
Conclusions: Occurrence of retinal hemorrhage warrants careful follow-up for multiple sclerosis patients treated
with fingolimod.
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Background
Fingolimod (Gilenya®, Novartis, Emeryville, CA, USA) is
the first oral agent used for treatment of relapsing-
remitting multiple sclerosis (RRMS). Macular edema (ME)
is a well-known adverse effect of fingolimod treatment,
occurring in approximately 0.4 % of patients [fingolimod-
associated macular edema (FAME)] [1]. However, retinal
hemorrhage has been almost unrecognized as a side effect
of fingolimod treatment. We therefore report a case of
extensive flame-shaped retinal hemorrhages in a patient
treated with fingolimod.
Case presentation
A 31-year-old male with a 13-year history of RRMS,
after fingolimod treatment for 1 month, was diagnosed
with ME and retinal hemorrhages in his left eye at a regu-
lar ophthalmic examination. His past history revealed that
the onset of MS was accompanied by a visual disorder. He
presented with several gadolinium-enhanced active lesions
in his brain, despite therapies of steroid pulse, plasma
exchanges, immunoglobulin, and interferon-beta (−β).
Although interferon-β was used for a period of 6 months,
6 years prior, it was discontinued because of allergic skin
reactions. The symptoms had improved after undergoing
a course of five plasma exchanges 5 years prior but the
patient refused further treatment. Over several years, the
patient had developed paralysis in his right upper limb,
both lower limbs, and had severe urinary incontinence
and constipation. His Expanded Disability Score Scale
(EDSS) was 8.5. Anti-aquaporin-4 antibody tested nega-
tive. Laboratory studies, including bleeding and coagu-
lation tests, were within normal limits. He had no
history of hypertension (blood pressure approximately
90–105/50–75 mmHg), diabetes mellitus, or hematological
diseases. When retinal hemorrhages were recognized, the
hemoglobin level was 15.0 g/dL and the platelet count was
210,000/μL (within the normal range). The patient had no
history of uveitis and pars planitis.
At the first ophthalmological examination before tak-
ing fingolimod, his corrected visual acuity was 20/600
OD and 20/400 OS, optic disc color was pale, and spec-
tral domain optical coherence tomography (SD-OCT)
showed a thinner retina (particularly in the nerve fiber
layer) without ME in both eyes (Fig. 1). This was
regarded as the cause of decreased visual acuity. In all
directions, the patient showed gaze-evoked nystagmus.
Four weeks after fingolimod treatment, his left eye
revealed extensive flame-shaped retinal hemorrhages
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along retinal arteries and veins (Fig. 2) as well as cystic
ME, as measured by SD-OCT (Fig. 3). His visual acuity
did not decrease considerably, with 20/600 OD and 20/
500 OS. Most of the hemorrhages were found along
both retinal arteries and veins beyond the mid-periphery
involving all four quadrants of the retina. Deeper dot-blot
hemorrhages, and a hemorrhage on the optic disc at the 12
to 1 o’clock position, were also recognized. The diameter
and tortuosity of the retinal veins after the hemorrhages
were the same as before the hemorrhages. Both eyes had
no inflammatory signs in the anterior segment and vitre-
ous, as assessed by slit lamp biomicroscopy examination.
Fingolimod was discontinued. Because FAME remained
for 13 weeks, topical treatment with 0.1 % betamethasone,
four times daily, was started. FAME was resolved com-
pletely 4 weeks after starting topical steroid therapy; that
was 17 weeks after the cessation of fingolimod. Retinal
hemorrhages remained unchanged for 4 weeks after the
cessation of fingolimod treatment, then started to decrease
and disappeared completely at 24 weeks, indicating that
the hemorrhages existed for 7 weeks longer than the
FAME. During the treatments and follow-ups, neither
retinal hemorrhages nor ME developed in the right eye.
The patient’s visual acuity at the time of disappearance of
retinal hemorrhages and FAME was 20/400 OD and 20/
400 OS. Fluorescein angiography was not performed
because the patient could not retain a sitting position.
Discussion
This case study revealed extensive flame-shaped retinal
hemorrhages in addition to ME, following fingolimod
treatment. The retinal hemorrhages were mainly present
Fig. 1 Spectral domain optical coherence tomography (SD-OCT) scans of both eyes before fingolimod treatment. The thinning of retinal nerve
fiber layers was recognized, with (a) showing horizontal and (b) showing vertical images in the right eye, and (c) showing horizontal and (d)
showing vertical images in the left eye. Because of the patient’s nystagmus, the precise averaging of multiple SD-OCT B-scans was not possible,
so single B-scan images are shown
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at the mid-periphery. There were no differences of ret-
inal vein dilatation and tortuosity before and after hem-
orrhaging. The hemorrhage pattern was considered to
be different from that of central or branch retinal vein
occlusion. The patient had no history of hypertension, dia-
betes mellitus, or hematological diseases. Eales disease
and tuberculous vasculitis also cause uni/bilateral periph-
eral retinal hemorrhages. Although the purified protein
derivative (PPD) skin test was not done, the hemorrhages
gradually disappeared completely in 24 weeks without oral
corticosteroid or anti-tuberculosis treatment after fingoli-
mod was discontinued. There were no signs of vascular
occlusion or retinal neovascularization that are often rec-
ognized in Eales disease.
To our knowledge, there has been only one report of a
macular hemorrhage without apparent causes following
treatment with fingolimod [2] that was completely resolved
soon after discontinuation of fingolimod. This case report
suggests that fingolimod may play a role in disrupting
vascular integrity, because hemorrhages are not routinely
seen in MS patients without other signs of uveitis.
FAME is a well-known side effect of fingolimod. The
sphingosine-1-phosphate (S1P) receptor plays a role in
regulating vascular permeability, and enhancing endo-
thelial barrier integrity. Fingolimod, a structural analog
of S1P, inhibits this barrier action and leads to increased
vascular permeability [3]. This may be the pathophysio-
logical mechanism involving FAME.
Lightman et al. reported that cases of acute optic neur-
itis are characterized by retinal vascular abnormalities
[4]. Their fluorescein angiograms showed multiple site
leakage in the mid-peripheral retina. Optic neuritis pa-
tients with vascular abnormalities have a tendency to de-
velop MS [4]. Recently, microcystic ME, predominantly
affecting the inner nuclear layer, was reported in 4.7 %
of patients with MS, and was more common in eyes with
higher Multiple Sclerosis Severity Scores [5]. The pres-
ence of microcystic ME in MS suggests that there may
Fig. 2 Color fundus photography of the patient. Flame-shaped hemorrhages are seen along the retinal arteries and veins in the left eye 1 month after
starting fingolimod treatment. Deeper dot-blot hemorrhages, and a hemorrhage on the disc at the 12 to 1 o’clock position, were also recognized.
Moderate macular edema is also shown
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be a breakdown of the blood-retinal barrier and tight
junction integrity [5]. These observations suggest that
the mid-peripheral retinal hemorrhages described in the
present case report may have been associated with MS-
associated uveitis, and could have introduced blood ret-
inal barrier disruption.
In the present case, we found thinning of nerve fiber
layers at the same level in both eyes, but it was only in
the left eye that ME and retinal hemorrhages were devel-
oped. In FAME, 74 % of onset is the single eye onset
type [6]. In microcystic edema in MS, two-thirds of the
cases are reported as the single eye onset type [5]. The
cause of symptom development in only a single eye is
unclear, but MS patients are known to develop multiple
and asymmetric symptoms.
Our case report suggests that not only multiple sclerosis
inflammatory disease, but also MS treatment with fingoli-
mod, may lead to an increase in vascular permeability in
some patients. Besides FAME, in severe cases of MS with
persistent inflammation, fingolimod may also cause retinal
hemorrhage.
Conclusions
Occurrence of retinal hemorrhages warrants careful
follow-up of MS patients treated with fingolimod.
Consent
Because the patient could not move his hands smoothly,
written informed consent was obtained from the pa-
tient’s mother for publication of this case report and ac-
companying images. A copy of the written consent is
available for review by the Editor of this journal.
Ethics approval
Approval for this work was obtained from the Hakuaikai
Ethics Committee of Kyoto, Japan.
Fig. 3 Spectral domain optical coherence tomography (SD-OCT) scans through the fovea. a Four weeks after starting fingolimod treatment,
SD-OCT showed cystoid macular edema in the left eye. At that time, fingolimod was terminated. b Three weeks and (c) 13 weeks after cessation
of fingolimod treatment, macular edema was still present. Topical betamethasone treatment began at 13 weeks. d Macular edema resolved
4 weeks after topical steroid treatment. Because of the patient’s nystagmus, the precise averaging of multiple SDOCT B-scans was not possible,
and single B-scan images are shown
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